Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers

a breast cancer and hormone-resistant technology, applied in the field of primary hormone-resistant endometrial and breast cancer treatment, can solve the problems of no treatment option for patients with recurrent or metastatic endometrial carcinoma, and the depletion of prs in the target tissue of progestin treatmen
US20170202854A1Inactive Publication Date: 2017-07-20LIPOXEN TECHNOLOGIES LTD
0 Cites 4 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
LIPOXEN TECHNOLOGIES LTD
Publication Date
2017-07-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
Patent Text Reader

Abstract

The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 62 / 076,546, filed on Nov. 7, 2014, the disclosure of which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION

[0002] The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.BACKGROUND OF THE INVENTION

[0003] Endometrial cancer is one of the most common invasive gynecologic cancers. Currently no therapy of recurrent or metastatic e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More